Search:

Analyses of TPP and Access to Medicines Archive

Public Citizen's analyses

Dangers for Access to Medicines in the Trans-Pacific Free Trade Agreement: Comparative Analyses of the U.S. IP proposal to the Trans-Pacific FTA and existing laws in TPP countries
      Australia
      Malaysia
      Peru (en Español)
      Vietnam (summary in Vietnamese)
Comparative Chart of Pharmaceutical Patent and Data Provisions in the TRIPS Agreement, Free Trade Agreements between Trans-Pacific FTA Negotiating Countries and the U.S. and the U.S. Proposal to the Trans-Pacific FTA (December, 2011)
Memo: Leaked New Zealand Paper Challenges Past U.S. FTA Models in Trans-Pacific Trade Negotiations, Access to Medicines at Stake (December, 2010)

Joint analyses

Risks of the Trans-Pacific FTA for Access to Medicines: Analysis of the Leaked U.S. Paper on Eliminating Pre-Grant Opposition, Public Citizen; Health Global Access Project; Initiative for Medicines, Access & Knowledge; Third World Network (July 2011)
Civil Society Comments on the Trans-Pacific Partnership Agreeement, Doctors Without Borders/Médecins Sans Frontières, Health Action International-Global, Health Global Access Project, Knowledge Ecology International, National Legislative Association on Prescription Drug Prices, Oxfam America, Public Citizen, Universities Allied for Essential Medicines (May 2011) (link to keionline.org)
Analysis of the Leaked New Zealand Paper on the Trans-Pacific Partnership Agreement and Intellectual Property, Third World Network, Public Citizen (December 2010)

Further analyses

U.S. Trade-Enhancing Access to Medicines (Access Window) in its proposed TPP IP text is a sham, Brook Baker, Northeastern University School of Law and Health Global Access Project (October, 2011) (link to infojustice.org)
Oxfam America Analysis of the USTR Trade Enhancing Access to Medicines (TEAM) White Paper, Oxfam America
Oxfam Analysis of U.S. Proposals for IP and Pharmaceutical Pricing Provisions in Trans-Pacific Partnership Agreement Negotiations, Oxfam America
Comments for the Record to the Subcommittee on Trade of the Committee on Ways and Means--Hearing on the Trans-Pacific Partnership Agreement (TPPA), Knowledge Ecology International (link to keionline.org)
Public Interest Analysis of the U.S. TPP Proposal for an IP Chapter, American University Washington College of Law Program on Information Justice and Intellectual Property (PIJIP), Sean Flynn (Associate Director, PIJIP), Margot Kaminski (Yale Law School, Executive Director, Information Society Project), Brook Baker (Northeastern University School of Law, Program on Human Rights and the Global Economy; Health Global Access Project), Jimmy Koo (Fellow, PIJIP) (December 2011) (link to infojustice.org)
How the Trans-Pacific Partnership Agreement Threatens Access to Medicines, Médecins Sans Frontières (September, 2011) (link to doctorswithoutborders.org)
Why the Trans-Pacific Partnership Should Not Include Pharmaceutical Pricing Provisions, American University Washington College of Law Program on Information Justice and Intellectual Property (PIJIP) (December 2010)

Back to Leaked Trade Negotiations Text and Analyses

Back to Trans-Pacific FTA Page

Back to Access to Medicines Home Page

Copyright © 2013 Public Citizen. All rights reserved. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation.
Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.